| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.063 | 0.05 |
| mRNA | BRD-K19103580 | CTRPv2 | pan-cancer | AAC | -0.07 | 0.05 |
| mRNA | Ispinesib Mesylate | GDSC1000 | pan-cancer | AAC | 0.061 | 0.05 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | -0.068 | 0.06 |
| mRNA | Merck60 | CTRPv2 | pan-cancer | AAC | -0.056 | 0.06 |
| mRNA | VX-680 | CTRPv2 | pan-cancer | AAC | 0.18 | 0.06 |
| mRNA | Obatoclax Mesylate | GDSC1000 | pan-cancer | AAC | 0.066 | 0.06 |
| mRNA | KU-55933 | CTRPv2 | pan-cancer | AAC | -0.067 | 0.06 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | -0.063 | 0.06 |
| mRNA | GDC-0941 | gCSI | pan-cancer | AAC | 0.11 | 0.06 |